Blog

Results from the Phase 3 NADINA Clinical Trial – Melanoma Institute Australia

A collage photo of Georgina Long and Christian Blank

Jun 6, 2024, 02:56

Results from the Phase 3 NADINA Clinical Trial – Melanoma Institute Australia

Melanoma Institute Australia posted on LinkedIn:

“Heralded as a cancer treatment revolution, the pre-surgery (neoadjuvant) use of combination immunotherapy looks set to become standard treatment for melanoma, and to impact other cancers across the globe.

Ground-breaking results from the Phase 3 NADINA Clinical Trial, an international collaboration co-led by MIA’s Prof Georgina Long and Prof Christian Blank from The Netherlands Cancer Institute.”

Source: Melanoma Institute Australia/LinkedIn

cancer Christian Blank combination immunotherapy Georgina Long Melanoma Melanoma Institute Australia NADINA Clinical Trial OncoDaily Oncology The Netherlands Cancer Institute

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer